Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9153228 | 0.83 | RAB9A (0.55) | ALDH1A1KMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL5053681 | 0.82 | CA12 (0.45) | ALDH1A1KMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL3236020 | 0.77 | ALDH1A1 (0.60) | ALDH1A1CYP19A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL1194908 | 0.77 | ALDH1A1 (0.57) | ALDH1A1CYP19A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL3236036 | 0.77 | ALDH1A1 (0.60) | ALDH1A1CYP19A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL1194905 | 0.77 | ALDH1A1 (0.57) | ALDH1A1CYP19A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL28460573 | 0.77 | CYP19A1 (0.76) | ALDH1A1CYP19A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL28460574 | 0.77 | CYP19A1 (0.76) | ALDH1A1CYP19A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6015558 | 0.75 | CYP1A2 (0.51) | ALDH1A1KMT2ASMN1; SMN2HPGDMAPT | |
| SCHEMBL3825495 | 0.75 | PTPN1 (0.67) | ALDH1A1KMT2ANPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5994345-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | claimed |
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | disclosed |
| EP-1716155-A1 | SUBSTITUTED THIENO¬2,3-D|PYRIMIDINES AS INHIBITORS OF TIE2 | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075483-A1 | SUBSTITUTED THIENO - AND THIAZOLO - [2, 3-D] PYRIDINES AS INHIBITORS OF TIE2 | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| EP-1129207-A1 | CATALYTIC ANTIBODIES AND METHOD FOR PRODUCING CHROMANES BY CYCLIZATION WITH SAID ANTIBODIES | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000028063-A1 | CATALYTIC ANTIBODIES AND METHOD FOR PRODUCING CHROMANES BY CYCLIZATION WITH SAID ANTIBODIES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000028330-A1 | METHOD FOR SELECTING CATALYTIC ANTIBODIES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027884-A1 | ANTIBODIES, MINI-ANTIBODIES OR ANTIBODY FRAGMENTS BINDING TO VITAMIN E AND THE USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
| EP-0247431-A1 | Substituted 6-hydroxymethylcarbapenem antibiotics, process for their preparation and their use | BAYER AG (DE) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | NRAS, BRAF, MAPK1 | ALDH1A1 1951/4885CYP19A1 1425/4885KMT2A 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.